Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment source : Www.biospace.com save search
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
LEGN | News | $47.06 1.88% 1.87% 760K
|
Health Technology
|
| O: 0.39%
H: 1.73%
C: 1.49%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
carvykti approved treatment for
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.0%
H: 1.92%
C: 1.0%
emblaveo treatment for infections
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
ACAD | News | $16.99 1.01% 1.06% 820K
|
Health Technology
|
| O: 1.37%
H: 1.7%
C: -0.35%
drug health review treatment pharmaceuticals for canada submission
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $30.06 -2.4% 0.0% 1.4M
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $107.07 -0.2% 0.18% 3.8M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
first treatment for
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | $126.94 0.92% 0.32% 4.8M
|
Health Technology
|
| O: 0.22%
H: 0.37%
C: 0.1%
health treatment for canada advanced keytruda
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | $4.3 -7.53% -4.49% 17K
|
Health Technology
|
| O: 4.91%
H: 11.36%
C: 0.67%
drug treatment designation for grants leukemia
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
EVO | $7.36 4.1% 5.35% 34K
|
Manufacturing
|
| O: 0.42%
H: 0.0%
C: 0.0%
partnership fibrosis
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.51 5.02% 5.53% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $12.89 -3.3% -3.25% 800K
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: -1.47%
H: 2.05%
C: -0.59%
nulibry authorization treatment for therapeutics
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 0.0%
H: 14.29%
C: -7.14%
patent cancer biopharma for grant
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.55 -1.3% -1.32% 280K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta abbvie treatment for migraine
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.95 0.29% 0.28% 3.8M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7342 -2.68% -2.93% 1.3M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: 1.47%
H: 1.16%
C: -1.27%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: 3.34%
H: 0.27%
C: -0.62%
children approved treatment for
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.74 -1.58% -1.06% 55K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Published: 2024-04-10 (Crawled : 11:00) - biospace.com/
TBPH | $9.46 1.29% 1.27% 310K
|
Health Technology
|
| O: -1.37%
H: 2.14%
C: 2.03%
treatment system for key potential
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $4.99 9.91% 9.02% 150K
|
Health Technology
|
| O: 2.16%
H: 23.21%
C: 16.03%
fda treatment designation for aml
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.95 1.44% 1.51% 190K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | $18.0825 -3.3% -1.71% 2.9K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.